Endocannabinoids (Endocannabinoid)

Subscribe to Selected New Research on Endocannabinoids

609 relevant articles (25 outcomes, 84 trials/studies) found for this Bio-Agent

Description: Endogenous compounds that bind to CANNABINOID RECEPTORS. They are structurally different from the CANNABINOIDS which are primarily derived from plants.

Also Known As:

Endocannabinoid; Cannabinoids, Endogenous; Endogenous Cannabinoids; Cannabinoid Receptor Modulators; Modulators, Cannabinoid Receptor; Receptor Modulators, Cannabinoid

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses

Pharmacologic Actions: 50

Molecular Mechanisms of Pharmacological Action: 5

Neurotransmitter Agents: 5439

Endocannabinoids: 609

Physiological Effects of Drugs: 1

Hormones, Hormone Substitutes, and Hormone Antagonists

Hormones: 44075

Endocannabinoids: 609

Experts

1.	Di Marzo, Vincenzo: 26 articles (08/2008 - 06/2002)
2.	Di Marzo, V: 11 articles (08/2008 - 01/2000)
3.	Petrosino, Stefania: 10 articles (08/2008 - 07/2005)
4.	Maccarrone, Mauro: 9 articles (10/2007 - 08/2002)
5.	Kunos, George: 8 articles (10/2008 - 10/2004)
6.	Bátkai, Sándor: 7 articles (10/2008 - 10/2004)
7.	Pacher, Pál: 7 articles (10/2008 - 10/2004)
8.	Bisogno, Tiziana: 7 articles (01/2008 - 12/2002)
9.	Bifulco, Maurizio: 7 articles (05/2007 - 06/2002)
10.	Osei-Hyiaman, Douglas: 6 articles (05/2008 - 10/2004)

Related Diseases

1.	Obesity 05/01/2005 - "Endogenous cannabinoids acting at CB(1) receptors stimulate appetite, and CB(1) antagonists show promise in the treatment of obesity" 01/01/2007 - "Results of this and other studies support the role of endocannabinoids in the development and maintenance of obesity" 01/01/2006 - "Some studies suggest that endocannabinoid formation is increased in obesity, perhaps because endocannabinoid degradation is decreased" 09/01/2008 - "Obesity leads to excessive endocannabinoid production by adipocytes, which drives CB(1) in a feed-forward dysfunction" 08/27/2008 - "Endocannabinoid system is overactivated in individuals with abdominal obesity" Get all the results and reference details, order at left...
2.	Pain (Aches) 02/01/2007 - "Yet to be developed substances that inhibit both endocannabinoid and PEA inactivation might be useful for the treatment of neuropathic pain." 11/01/2007 - "Herein we review recent studies of the effects of inhibition of metabolism of endocannabinoids versus uptake of endocannabinoids on nociceptive processing in models of inflammatory and neuropathic pain." 10/01/2004 - "Here, we review recent genetic, behavioral, and pharmacological studies that have tested the function of the endocannabinoid system in pain sensation" 10/01/2008 - "The endocannabinoid system can reduce pain sensitivity" 09/04/2008 - "Endocannabinoid system can reduce pain sensitivity" Get all the results and reference details, order at left...
3.	Stroke (Strokes) 11/13/2008 - "Although several in vivo and in vitro studies confirmed the neuroprotective efficacy of endocannabinoids, no experimental settings compare and explore the neuroprotective potential of AEA and PEA in an acute stroke model" 10/01/2007 - "Deficiencies in our knowledge of endocannabinoids in the etiology and pathogenesis of stroke, caveats and limitations of existing studies, and future directions for investigation will be addressed." 11/13/2008 - "Both endocannabinoids may have the potential to treat acute stroke and exert neuroprotection through a variety of mechanisms." 10/01/2007 - "Variability in experimental stroke models and modes of outcome evaluation, however, have provoked controversy regarding the precise roles of endocannabinoid signals in mediating neural and/or vascular protection versus neurovascular damage" 12/01/2007 - "Endocannabinoids might form the basis for the development of new neuroprotective drugs useful for the treatment of stroke and other neurodegenerative pathologies." Get all the results and reference details, order at left...
4.	Myocardial Infarction 08/01/2006 - "Improved cessation rates are under active study and include behavioral methods, targeting smokers immediately after myocardial infarction, consideration of depression in smokers, pharmacogenomics to identify persons who may respond more favorably to specific interventions, and newer medications that affect endocannabinoid receptors." 04/01/2003 - "Endocannabinoids as mediators in the heart: a potential target for therapy of remodelling after myocardial infarction?" 12/01/2001 - "OBJECTIVES: We sought to determine whether endocannabinoids influence hemodynamic variables in experimental models of acute myocardial infarction (MI)" 01/01/2008 - "However, there is evidence suggesting that endocannabinoids are overproduced during various forms of I/R, such as myocardial infarction or whole body I/R associated with circulatory shock, and may contribute to the cardiovascular depressive state associated with these pathologies" 02/01/2004 - "Current evidence suggests that endocannabinoids have important protective roles in pathophysiological conditions such as shock and myocardial infarction" Get all the results and reference details, order at left...
5.	Inflammation 08/01/2008 - "The endocannabinoid (EC) system mediates protection against intestinal inflammation" 08/01/2007 - "The aim of the study was to investigate if the endocannabinoid system (ECS) is activated in visceral adipose tissue and if adipose tissue inflammation affects the ECS activation state" 11/01/2008 - "Prostamides may play an important role in gastrointestinal inflammation, particularly given the enhanced expression of both COX-2 and endocannabinoids that occurs in the inflamed gut" 10/18/2008 - "Endocannabinoid system and bowel inflammation.]" 08/01/2008 - "Drugs that alter the levels of endocannabinoids in the gut also reduce motility and attenuate inflammation" Get all the results and reference details, order at left...
192 Diseases and 609 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	rimonabant
2.	Cannabinoid Receptors (Cannabinoid Receptor)
3.	palmidrol
4.	anandamide (arachidonylethanolamide)
5.	CB1 Cannabinoid Receptor (CB1 Receptor)
6.	fatty-acid amide hydrolase (fatty acid amide hydrolase)
7.	Ligands
8.	N-(4-hydroxyphenyl)arachidonylamide (AM404)
9.	Neuroprotective Agents
10.	Polymyxin B (Aerosporin)
177 Drugs and Important Bio-Agents and 320 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Hemoperfusion
2.	Analgesia
3.	Ligation
4.	Renal Dialysis (Hemodialysis)
5.	Therapeutics
12 Therapies and Procedures and 24 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>